These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 9026943)
21. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin]. Mazo EB; Matushevskiĭ IA; Nikitin IuIu Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799 [TBL] [Abstract][Full Text] [Related]
22. The role of combination medical therapy in benign prostatic hyperplasia. Greco KA; McVary KT Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123 [TBL] [Abstract][Full Text] [Related]
23. Effects of 5 alpha-reductase inhibition by finasteride on lipoproteins and body composition in males affected by benign prostatic hyperplasia (BPH). Denti L; Pasolini G; Cortellini P; Sanfelici L; Benedetti R; Cecchetti A; Ferretti S; Banchini A; Ablondi F; Valenti G J Endocrinol Invest; 1999; 22(10 Suppl):70-1. PubMed ID: 10727053 [No Abstract] [Full Text] [Related]
24. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586 [TBL] [Abstract][Full Text] [Related]
25. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia. Roehrborn CG Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120 [TBL] [Abstract][Full Text] [Related]
26. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717 [TBL] [Abstract][Full Text] [Related]
27. [Clinical experience with oxendolone for treatment of benign prostatic hyperplasia. Clinical efficacy and effects on serum lipid and lipoprotein fraction levels]. Yasukawa A; Nihira H; Matsuki S; Fujii M; Fujiwara H; Kitano T; Kodama M; Ukai R; Tado O; Sagami K Hinyokika Kiyo; 1984 Apr; 30(4):537-43. PubMed ID: 6207714 [TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: a retrospective multi-institutional study. Fujimoto K; Hirao Y; Masumori N; Arai Y; Yamanaka H; Kato T; Miyazawa K Int J Urol; 2006 May; 13(5):543-9. PubMed ID: 16771723 [TBL] [Abstract][Full Text] [Related]
31. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml]. Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891 [TBL] [Abstract][Full Text] [Related]
32. [Impact of prostatic benign hyperplasia and prostatic inflammation on the increase of prostate specific antigen levels]. Ferrero Doria R; Pérez Flores D; Terrer Artes C; Guzmán Martínez-Valls PL; Morga Egea JP; Tomás Ros M; Rico Galiano JL; Sempere Gutiérrez A; Fontana Compiano LO Actas Urol Esp; 1997 Feb; 21(2):100-4. PubMed ID: 9214204 [TBL] [Abstract][Full Text] [Related]
33. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer. Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656 [TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy. Soga N; Onishi T; Arima K; Sugimura Y Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253 [TBL] [Abstract][Full Text] [Related]
35. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia]. Xu J; Qian WQ; Song JD Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754 [TBL] [Abstract][Full Text] [Related]
36. [Study on patients with benign prostate hyperplasia treated by the therapeutic regimen of watchful waiting during a twenty-four-month follow-up period]. Zhang YG; Wang JY; Liu M; Xu J; Wu JY; Xin Y; Wan B; Wei D; Zhu SC; Zeng P Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):611-3. PubMed ID: 19040049 [TBL] [Abstract][Full Text] [Related]
37. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. Yamanishi T; Yasuda K; Kamai T; Tsujii T; Sakakibara R; Uchiyama T; Yoshida K Int J Urol; 2004 Jul; 11(7):501-9. PubMed ID: 15242359 [TBL] [Abstract][Full Text] [Related]
38. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461 [TBL] [Abstract][Full Text] [Related]
39. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate]. Lopatkin NA; Loran OB; Pushkar' DIu; Perepanova TS; Tevlin KP Urol Nefrol (Mosk); 1998; (3):3-5. PubMed ID: 9644978 [TBL] [Abstract][Full Text] [Related]
40. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels. Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]